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Background: High mobility group box 1 (HMGB-1), a ligand of the receptor for advanced glyca-
tion end products (RAGE), is an inflammatory mediator in various disorders. Its endogenous
decoy inhibitor, endogenous secretory RAGE (esRAGE), prevents the activation of RAGE
signaling, and imbalance between HMGB-1 and esRAGE is known to be a factor determining
progression of chronic inflammatory diseases.
Methods: We measured HMGB-1 and esRAGE levels in induced sputum from 44 asthmatic
patients and 15 normal controls, and examined their correlations with asthma indices including
pulmonary function test values and induced sputum indices.
Results: HMGB-1 levels in induced sputum were significantly higher in asthmatic patients
than in normal controls (p < 0.001). Similarly, esRAGE levels were significantly higher in
asthmatic patients than in normal controls (p < 0.001). In asthmatic patients, HMGB-1 levels
were inversely correlated with percentage of predicted forced expiratory volume in 1 s (%
FEV1) and FEV1/forced vital capacity (FEV1/FVC). There was a significant increase in
HMGB-1 level associated with severity of asthma (p < 0.001). However, there was no signif-
icant increase in esRAGE level associated with severity of asthma. In asthmatic patients,
HMGB-1 levels were significantly correlated with percentage of neutrophils in induced
sputum.ion end products; esRAGE, endogenous secretory RAGE; FEV1, forced expiratory volume in 1 s; FVC,
bility group box 1; ICAM-1, intercellular adhesion molecule-1; %FEV1, percentage of predicted forced
tor for advanced glycation end products; VCAM-1, vascular cell adhesion molecule-1.
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520 T. Watanabe et al.Conclusions: Our findings suggest that the HMGB-1 is a mediator of neutrophilic airway
inflammation in asthma and that imbalance between HMGB-1 and esRAGE is related to the
severity of asthma. Combined measurement of HMGB-1 and esRAGE may be novel biomarkers
in asthma with severe airflow limitation.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Asthma is a chronic airway inflammatory disease associated
with airway wall remodeling.1 The airway inflammation in
asthma is characterized by a complex immunopathology
involving several different cell types and mediators, and
inhaled corticosteroids (ICS) have been key therapeutic
drugs in controlling this type of inflammation. The condi-
tion of some asthmatic patients is more severe and they
consume much larger amounts of medical resources than
those with less severe asthma. Severe asthma is strongly
associated with death due to asthma. Particularly, asthma
with increased risk of mortality was associated with the
degree of airflow limitation.2 It is thus essential to examine
the characteristics of the asthma with severe airflow limi-
tation and to determine new biomarkers and novel strate-
gies for controlling it. Both resident and recruited
inflammatory cells promote acute and chronic inflammation
leading to persistent lung dysfunction due to structural
remodeling. Many authors have reported that neutrophilic
inflammation is involved in severe asthma.3e5 Neutrophilic
airway inflammation is considered to induce airway damage
leading to the development of the fixed airflow limitation,
which is characteristic of severe asthma.6
A 30 kDa protein termed high mobility group box 1
(HMGB-1) was first purified from nuclei with histones.7,8
HMGB-1 is produced by many types of cells, and is located
in both the cytoplasm and nucleus. Recently, HMGB-1 was
found to be actively released in response to stimulation
with endogenous proinflammatory cytokines such as tumor
necrosis factor (TNF)-a, interleukin (IL)-1b, and interferon
(IFN)-g from inflammatory and structural cells including
activated monocytes, macrophages, and neutrophils.9e11
Moreover, HMGB-1 up-regulates the expression of endo-
thelial adhesion molecules such as intercellular adhesion
molecule-1 (ICAM-1) and vascular cell adhesion molecule-1
(VCAM-1) for inflammatory cell recruitment.12 Conse-
quently, HMGB-1 can mediate and enhance local and
systemic inflammation. HMGB-1 has attracted much atten-
tion as an important mediator in inflammatory diseases
such as atherosclerosis, arthritis, collagen disease, cancers,
sepsis, and acute lung injury.13e19 HMGB-1 can bind to the
receptor for advanced glycation end products (RAGE) in
concentration-dependent fashion.20 RAGE is a member of
the immunoglobulin superfamily, and is expressed on
inflammatory cells and many structural cells.21,22 RAGE
interacts with a variety of ligands including advanced gly-
cation end products (AGEs), amyloid peptide, S100 proteins
and HMGB-1. Engagement of RAGE with its ligands activates
various intracellular signaling pathways. Structural/func-
tional studies revealed that a motif (amino acids 150e183)
in the C-terminus of HMGB-1 was responsible for RAGE
binding,23 and extracellular HMGB-1-induced signalingpathway activation has been reported to be inhibited by
blocking antibodies to RAGE. Endogenous secretory RAGE
(esRAGE) is a splice variant of RAGE and has a ligand-
binding V-domein. esRAGE has ligand-binding activity and
decoy function, and is known to be present in the circula-
tion in humans.24 The decoy function of esRAGE features
a feedback mechanism by which esRAGE prevents the
activation of RAGE signaling, and low circulating esRAGE
levels are known to be a predictor of RAGE-mediated
pathological conditions such as atherosclerosis and cardio-
vascular events in patients with end-stage renal disease.25
However, the role of HMGB-1 in the pathogenesis of
asthma and the involvement of the esRAGE feedback
system in HMGB-1-mediated inflammatory responses in
asthma are not yet fully understood. We hypothesized that
the HMGB-1/RAGE signaling axis plays an important role in
the pathogenesis of asthma and that the esRAGE feedback
system plays a role in inhibiting the development of airway
inflammation. To test this hypothesis, we examined HMGB-
1 and esRAGE levels in induced sputum from asthmatic
patients and normal controls and examined their correla-
tions with asthma indices including pulmonary function test
values and induced sputum indices.Materials and methods
Subjects
A total of 44 asthmatic patients and 15 normal controls were
enrolled in this study. All normal controls were healthy
volunteers without history of lung diseases. All subjects were
Japanese, non-smokers, and had no history of respiratory
infection for at least the 4-week period preceding the study.
All subjects gave written informed consent to participate in
this study, which was approved by the Ethics Committee of
Osaka City University (approval number: 1421). All asthmatic
patients were newly diagnosed according to the American
Thoracic Society (ATS) criteria for asthma26 andwere enrolled
before asthma treatment including inhaled corticosteroids.
Pulmonary function testswereperformed for all subjects, and
forced vital capacity (FVC) and forcedexpiratory volume in 1 s
(FEV1) were measured. In all asthmatic patients except for
subjects with severe airflow limitation (%FEV1 is less than
70%), methacholine inhalation challenge testing was per-
formed according to the recommendations of the ATS,27 and
they showed airway hyperresponsiveness to methacoline. All
asthmatic patients exhibited airway reversibility to inhaled
bronchodilator. The fraction of exhaled nitric oxide (NO) was
also measured for all subjects using a chemiluminescence
analyzer (SiEVER 280i NIPPON MEGACARE Co, Ltd, Tokyo,
Japan)witha resolutionof 1 part per billion (ppb) according to
the recommendations of the ATS.28 In addition, all patients
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(intermittent, mild persistent, moderate persistent, severe
persistent) based on symptoms, airflow limitation, and lung
functionvariabilityaccording to theGINA2006guidelines,29 as
patients recruitment and data acquisition were done from
2007 to 2009.
Sputum induction and processing
Sputum induction was performed in accordance to the ERS
guidelines as described previously.30,31 Spirometry was
performed before inhalation of 200 mg salbutamol via
a metered dose inhaler. All subjects were instructed to
wash their mouth thoroughly with water. They then inhaled
3% saline at room temperature, nebulized via an ultrasonic
nebulizer (NE-U12, Omron Co, Tokyo, Japan) at maximum
output. They were encouraged to cough deeply at 3-min
intervals, thereafter. After sputum induction, spirometry
was repeated. If the FEV1 declined, the subjects were
required to wait until it returned to the baseline value. The
volume of sputum samples was measured, and the samples
were voltexed with phosphate-buffered solution (PBS).
After that, the samples were divided into two portions. In
one portion, dithiothreitol (DTT; final concentration of
1 mM) (WAKO Pure Chemical Industries Ltd, Osaka, Japan)
was added and well voltexed and centrifuged at 400g for
10 min, and the cell pellet was resuspended. Slides were
prepared by cytospin (Cytospin 3: Shandon, Tokyo, Japan)
and stained by May-Grunwald-Giemsa for differential cell
counts. In another portion of the sputum sample, for assay
of HMGB-1 levels and esRAGE levels, no DTT was added to
avoid potential confounding effects of DTT. Then the
sputum supernatant diluted with PBS without DTT was
ultracentrifuged at 60000g for 60 min at 4 C to remove
contaminating cellular debris. This was stored at 70 C for
subsequent assay of HMGB-1 levels and esRAGE levels. Both
levels were measured in duplicated by quantitative sand-
wich enzyme immunoassays (HMGB-1 ELISA kit II; Shino-Test
co, Kanagawa Japan, esRAGE ELISA kit; B-Bridge Interna-
tional, Inc., Sunnyvale CA USA), and we used the mean of
the measurement values. As samples were diluted with PBSTable 1 Clinical characteristics of the study subjects.
Normal controls
Subject number 15
Gender (M/F) 7/8
Age 42 (31e54)
Asthma severity (1/2/3/4) e
FEV1 (% predicted) 106 (85e121)
FEV1/FVC (%) 86 (76e93)
Exhaled NO (ppb) 16.5 (13e19)
Induced sputum cell counts
Eosinophils (%) 0.1 (0e0.5)
Neutrophils (%) 19 (14e27)
Macrophages (%) 76 (68e85)
Lymphocytes (%) 0.9 (0.2e1.7)
Epithelial cells (%) 3.0 (0.5e5.8)
All values are median (range).
FEV1; forced expiratory volume in 1 s, FVC; forced vital capacity, Sub
Asthma severity; 1; intermittent, 2; mild persistent, 3; moderate perin sputum processing, we recalculate original concentration
by using dilution factor. All subjects produced an adequate
specimen of sputum; a sample was considered adequate if
the patient was able to expectorate at least 2 ml of sputum
and if the slides contained less than 10% of squamous cells
on differential cell counting.
Statistical analysis
All values were presented as medians (range). The compar-
isons between normal controls and asthmatic patients were
analyzed by ManneWhitney U-test. The comparisons among
asthmatic groups subdivided by severity were analyzed by
the KruskaleWallis test. When those comparisons were
significant, the nonparametric analyses of variance with
Bonferroni/Dunn’s post hoc test were done. The significance
of correlations was analyzed by Spearman’s rank correlation
coefficients. For all tests, findings of p < 0.05 were consid-
ered significant.
Results
The clinical characteristics of the study subjects are shown in
Table 1. There was no significant difference in gender
betweenasthmatic patients andnormal controls. Median age
of normal controls was significantly higher than that of
asthmatic patients. There was no significant difference in
age among the asthmatic subgroups. In contrast, %FEV1 and
FEV1/FVCwere significantly lower in asthmatic patients than
those in normal controls (%FEV1: p < 0.01; FEV1/FVC:
p < 0.01). Exhaled NO levels and percentages of eosinophils
in induced sputum were significantly higher in asthmatic
patients than those in normal controls (p < 0.01, p < 0.01,
respectively). HMGB-1 levels in induced sputum were also
significantly higher in asthmatic patients than those in
normal controls (median (range): normal controls:
0 (0e45.2) ng/mL; asthmatic patients: 91.5 (0e590) ng/mL;
p < 0.001, Fig. 1A). Similarly, esRAGE levels were signifi-
cantly higher in asthmatic patients than those in normal
controls (normal controls: 12.0 (0e31.9) pg/mL; asthmaticAsthmatic patients p-value
44 e
21/23 n.s.
34 (23e51) 0.001
7/12/19/6
78 (57e86) <0.001
68 (56e80) <0.001
32 (24e47) <0.001
9.4 (4.5e15.5) <0.001
24 (11e47) <0.01
60.5 (43e71) <0.001
1.55 (0.2e3.0) 0.003
3.75 (1.3e7.2) n.s.
ject gender; M; male, F; female.
sistent, 4; severe persistent.
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Figure 1 (A) Comparison of HMGB-1 levels in induced sputum
of normal controls and asthmatic patients. (B) Comparison of
esRAGE levels in induced sputum of normal controls and asth-
matic patients.
522 T. Watanabe et al.patients: 110.5 (0e358) pg/mL; p < 0.001, Fig. 1B). We
examined the correlations between HMGB-1 level and
exhaled NO level in asthmatic patients. There was no
significant correlation between HMGB-1 level and exhaled
NO level (r Z 0.253, p Z 0.098). However, HMGB-1 level
was significantly correlated with the degree of airflow limi-
tation (FEV1/FVC; r Z 0.593, p < 0.001, and %FEV1;
rZ 0.758, p < 0.001, Fig. 2).0
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Figure 2 Correlation between HMGB-1 and FEV1/FVC in
asthmatic subjects.We examined the correlations between percentages of
neutrophils in induced sputum, HMGB-1 level and esRAGE
level and severity of asthma. There were significant differ-
ences in percentages of neutrophils in induced sputum
among the four subgroups of asthma (p < 0.001, Fig. 3A). In
severe persistent asthmatic patients, there was significant
increase in percentages of neutrophils. In asthmatic
patients, there were also significant differences in HMGB-1
level among the four subgroups of asthma (p < 0.001,
Fig. 3B). Although esRAGE levels in mild persistent to severe
persistent asthmatic patients were significantly higher than
those in normal controls (p < 0.001), there were no signifi-
cant increase in esRAGE level associated with severity of
asthma (Fig. 3C). We tested the correlations between HMGB-
1 level and esRAGE level in normal controls, asthmatic
patients and in each asthmatic subgroup with the different
severity. However, there was no significant correlation
between HMGB-1 level and esRAGE level. In asthmatic
patients, there was a significant positive correlation
between HMGB-1 level and percentage of neutrophils in
induced sputum (r Z 0.729, p < 0.001, Fig. 4), however,
there was no significant correlation between esRAGE level
and percentage of neutrophils.Discussion
In this study, we found that HMGB-1 levels in induced
sputum from asthmatic patients were significantly higher
than those in induced sputum from normal controls. We
also found that HMGB-1 level was significantly correlated
with degree of airflow limitation. Moreover, we found that
HMGB-1 level was increased in accordance with the severity
of asthma. Exhaled NO is an easily measured marker of
airway inflammation, and is thought to especially represent
eosinophilic inflammation, a major feature of asthmatic
airways. However, previous studies have demonstrated no
significant difference in exhaled NO levels in asthmatics
with moderate versus severe disease, suggesting sensitive
biomarker for discriminating severe asthma from less
severe asthma is needed.32e34 In this study, HMGB-1 was
significantly elevated in accordance with airflow limitation,
but not associated with exhaled NO levels.
In this study, esRAGE levels in induced sputum from
asthmatic patients were significantly higher than those in
normal controls. These findings suggest that an esRAGE
feedback mechanism to prevent activation of the RAGE
signaling cascade may be present in asthmatic airways.
Decreased serum esRAGE levels are known to be associated
with various pathological conditions such as atherosclerosis
and cardiovascular events. When asthmatic patients were
subdivided into four subgroups by severity, esRAGE levels
differed significantly among the groups. The esRAGE levels
in mild persistent to severe persistent asthmatic patients
were significantly higher than those in normal controls.
Although HMGB-1 levels were increased in accordance with
the severity of asthma, there were no significant differ-
ences in esRAGE levels among the mild persistent to severe
persistent asthmatic patients. Although the regulation and
confounding factor of esRAGE expression in asthmatic
airways is still not well understood, the esRAGE feedback
mechanism might fail in asthmatic patients with more
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Figure 4 Correlation between HMGB-1 and percentage of
neutrophils in induced sputum of asthmatic patients.
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Figure 3 (A) Relationship between percentages of neutro-
phils in induced sputum and the severity of asthma. Values
differed significantly among the five groups (p < 0.001); *versus
normal controls, p < 0.05; xversus mild persistent asthmatic
patients, p < 0.001; #versus moderate persistent asthmatic
patients, p < 0.001. (B) Relationship between HMGB-1 level in
induced sputum and the severity of asthma. Values differed
significantly among the five groups (p < 0.001); *versus normal
controls, p < 0.05; xversus mild persistent asthmatic patients,
p < 0.01; #versus moderate persistent asthmatic patients,
p < 0.001. (C) Relationship between esRAGE level in induced
sputum and the severity of asthma. Values differed signifi-
cantly among the five groups (p < 0.001); *versus normal
controls, p < 0.01. Bars in the box represent the medians.
HMGB-1 and esRAGE in asthma 523severe airflow limitation, such as those in moderate
persistent or severe persistent. We simultaneously
measured HMGB-1 and esRAGE levels and we found that
esRAGE levels were not significantly increased in accor-
dance with asthma severity. This discrepancy between
HMGB-1 and esRAGE in severe asthma might be a cause of
severe airflow limitation and could be used as biomarkers of
severe asthma. Recently Smith and co-authors reported
that plasma soluble RAGE were reduced in COPD patients,
and was correlated with the severity of airflow limitation.35
Their result suggests failure in negative feedback for RAGE
signaling pathway is exists in severe chronic airway
inflammatory disease and their result supports our results.
HMGB-1 is known to be a neutrophilic chemoattractant,
so we examined the relationship between HMGB-1 and
percentage of neutrophils in induced sputum of study
subjects. As we shown, percentage of neutrophils in
induced sputum in severe asthmatic patients is significantly
higher compared with normal controls or less severe asth-
matic patients. In these subgroups, there is a significant
positive correlation between HMGB-1 level and the
percentage of neutrophils in induced sputum. Recent
studies have demonstrated that neutrophilic airway
inflammation has a pathologically important role in the
progression of persistent airflow limitation in severe
asthma.4e6 HMGB-1 might work as a neutrophilic chemo-
attractant and involved in novel pathway of inflammation
of severe asthma. The cellular source of HMGB-1 in induced
sputum is unclear. Asthma is an inflammatory airway
disease with involving a variety of inflammatory cells and
recruited inflammatory cells might be one of the sources of
HMGB-1. However, HMGB-1 is ubiquitously expressed in
various types of cells and not only inflammatory cells,
structural cells including epithelial or smooth muscle cell
are the possible sources of HMGB-1 in the airway. In an in
vitro model, HMGB-1 is passively released from necrotic
cells/tissue or actively secreted from certain immune cells
including macrophages, dendritic cells, and natural killer
cells during infection.36,37 In human lungs, HMGB-1 is
expressed in epithelial cells of airways and alveolar
macrophages38 and RAGE is highly expressed, particularly in
pulmonary endothelium, bronchiolar epithelium, alveolar
macrophages and type I alveolar epithelial cells.39,40 HMGB-
1 and its receptor RAGE are co-localized in airways and
524 T. Watanabe et al.HMGB-1 might work in paracrine manner. Extracellularly
transported HMGB-1 activates signaling pathways in endo-
thelial or epithelial cells such as the NF-kB signaling
pathway and the mitogen-activated protein kinase (MAPK)
through RAGE36,37 and thereby induces the production of
neutrophilic chemotactic cytokines/chemokines such as
TNF-a and IL-8.12 Moreover, HMGB-1 also activates MAPKs
(such as p38 and ERK1/2) and phosphatidylinositol
3-kinase/Akt and enhances the expression of proin-
flammatory cytokines in NF-kB-dependent fashion in
neutrophils.41 HMGB-1 augmented not only the neutrophil
recruitment but also the activation of neutrophils. These
findings suggest that the HMGB-1 signaling axis may induces
neutrophil recruitment and activation in the airways and
may plays an important role in neutrophilic inflammation in
asthmatic airways. HMGB-1 might thus be a new molecular
target for controlling neutrophilic airway inflammation.
In conclusion, we showed for the first time that HMGB-1
and esRAGE levels in induced sputum were significantly
higher from asthmatic patients than those in that from
normal controls. HMGB-1 level increased in accordance
with the severity of asthma, particularly the degree of
airflow limitation, and was correlated with the percentage
of neutrophils in induced sputum. esRAGE levels did not
increase in accordance with the severity of asthma and this
discrepancy between HMGB-1 and esRAGE might have
important roles in neutrophilic inflammation in asthmatic
airways. Combined measurement of HMGB-1 and esRAGE
could be new biomarkers reflecting severity of asthma and
neutrophilic inflammation in asthmatic airways. However,
our study is small and preliminary and further studies
addressing the roles of the HMGB-1/RAGE axis in asthmatic
airway inflammation are needed to obtain novel strategies
of treatment of asthma.
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